Previous Close | 0.2711 |
Open | 0.2600 |
Bid | 0.2779 x 1100 |
Ask | 0.2950 x 3000 |
Day's Range | 0.2600 - 0.2958 |
52 Week Range | 0.2410 - 3.9500 |
Volume | |
Avg. Volume | 603,112 |
Market Cap | 12.97M |
Beta (5Y Monthly) | N/A |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.7200 |
Earnings Date | Nov 13, 2020 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 6.00 |
Subscribe to Yahoo Finance Plus to view Fair Value for ADTX
RICHMOND, Va., April 14, 2022--Aditxt, Inc. ("Aditxt", or the "Company") (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, today is announcing a multiyear partnership with GRS, an affiliate of marketing powerhouse Guthy-Renker, LLC ("Guthy-Renker"). This partnership will focus on building awareness and visibility among consumers and healthcare providers for the AditxtScore™ Immune Monitoring Platform. Aditxt plans to work
RICHMOND, Va., April 05, 2022--Aditxt, Inc. ("Aditxt", or the "Company") (Nasdaq: ADTX) has entered into a revenue-sharing agreement with Cellvera, and certain of its affiliates. The agreement is designed to drive strategic revenue and growth starting in 2022 and provide enhanced security for the Company’s $14.5 million loan, plus interest to Cellvera Global Holdings LLC ("Cellvera"), formerly AiPharma Global Holdings LLC. The Company has signed the agreement as consideration for Aditxt’s separa
RICHMOND, Va., March 23, 2022--Aditxt, Inc. (Nasdaq: ADTX), a biotech innovation company developing technologies focused on mapping and reprogramming the immune system, announced today that Company CEO & Co-Founder, Amro Albanna, has been invited to present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th - 30th from 9:00 a.m. - 5:00 p.m. EDT.